UPDATE: Due to the high circulation of the SARS-CoV-2 Omicron variant, REGEN-COV is not currently authorized for use in any U.S. Region. Please refer to the authorized Fact Sheet and FDA statement for additional details.
Learn More
Skip to content

INVESTIGATIONAL PIPELINE A POWERFUL RESEARCH AND DEVELOPMENT ENGINE

PIPELINE & MEDICINES

INVESTIGATIONAL PIPELINE

Our pipeline is powered by end-to-end research and development capabilities. The Research team discovers promising new drug compounds. From there, Global Development brings these investigational candidates through the full clinical development process, from trial design to study execution and lifecycle management. Our product portfolio reflects the true collaborative spirit of Regeneron.

Explore the Regeneron clinical pipeline

Select therapeutic area(s):
Select phase(s):
Select collaborator(s):

Displaying item

Clear Filters

Phase 1

  • ALN-APP1
    APP RNAi Therapeutic Early-onset Alzheimer’s disease
    Neurology General Medicine
  • ALN-HSD1
    HSD17B13 RNAi Therapeutic Nonalcoholic steatohepatitis ("NASH")
    Immunology & Inflammation General Medicine
  • FIANLIMAB
    LAG-3 Antibody Solid tumors, advanced hematologic malignancies
    Oncology Hematology
  • LINVOSELTAMAB
    BCMA X CD3 Antibody Multiple myeloma
    Hematology
  • "NEXT GENERATION" COVID ANTIBODIES
    Antibodies to SARS-CoV-2 Variants Healthy volunteers
    Infectious Diseases General Medicine
  • NTLA-20013
    TTR gene knockout using CRISPR/Cas9 Transthyretin ("ATTR") amyloidosis
    Rare Diseases Hematology
  • ODRONEXTAMAB
    CD20 X CD3 Antibody Certain B-cell malignancies
    Oncology Hematology
  • REGN4336
    PSMA X CD3 Antibody Prostate cancer
    Oncology
  • REGN5093
    MET X MET Antibody MET-altered advanced NSCLC
    Oncology
  • REGN5093-M114
    MET X MET Antibody MET overexpressing advanced cancer
    Oncology
  • REGN5381/REGN9035
    Agonist Antibody to NPR1/Reversal Agent to REGN5381 Reversal agent in healthy volunteers
    Cardiovascular & Metabolic Diseases General Medicine
  • REGN5459
    BCMA X CD3 Antibody Transplant desensitization in patients with chronic kidney disease
    Oncology Hematology
  • REGN5668
    MUC16 x CD28 Antibody Platinum-resistant ovarian cancer
    Oncology
  • REGN5678
    PSMA X CD28 Antibody Prostate cancer
    Oncology
  • REGN6569
    GITR Antibody Solid tumors
    Oncology
  • REGN7075
    EGFR x CD28 Antibody Solid tumors
    Oncology
  • REGN7257
    IL-2Rg Antibody Aplastic anemia
    Hematology
  • REGN7999
    TMPRSS6 Antibody Transfusion dependent iron overload
    Hematology
  • REGN9933
    Factor XI Antibody Thrombosis
    Hematology

Phase 2

  • CEMDISIRAN1
    C5 siRNA Therapeutic Immunoglobulin A nephropathy
    Rare Diseases Hematology
  • CEMIPLIMAB
    PD-1 Antibody Metastatic or locally advanced CSCC, neoadjuvant CSCC, second-line cervical cancer ISA101b combination
    Oncology
  • DUPILUMAB5
    IL-4R alpha subunit Antibody Grass allergy
    Immunology & Inflammation
  • LINVOSELTAMAB
    BCMA X CD3 Antibody Multiple myeloma (potentially pivotal study)
    Oncology Hematology
  • MIBAVADEMAB
    Leptin receptor ("LEPR") Agonist Antibody Generalized lipodystrophy, partial lipodystrophy
    Cardiovascular & Metabolic Diseases Rare Diseases General Medicine
  • ODRONEXTAMAB
    CD20 X CD3 Antibody B-cell non-Hodgkin lymphoma ("B-NHL") (potentially pivotal study)
    Cardiovascular & Metabolic Diseases Oncology Hematology
  • POZELIMAB
    C5 Antibody CD55-deficient protein-losing enteropathy, monotherapy (potentially pivotal study)
    Rare Diseases Hematology
  • REGN5381/REGN9035
    Agonist Antibody to NPR1/Reversal Agent to REGN5381 Heart failure
    Cardiovascular & Metabolic Diseases General Medicine
  • SARILUMAB5
    IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis ("pcJIA"), systemic juvenile idiopathic arthritis ("sJIA")
    Immunology & Inflammation
  • UBAMATAMAB
    MUC16 X CD3 Antibody Platinum-resistant ovarian cancer
    Oncology
  • VIDUTOLIMOD
    TLR9 Immune Activator CSCC and Merkel cell carcinoma
    Oncology

Phase 3

  • AFLIBERCEPT 8MG2
    VEGF-Trap Wet AMD, DME
    Ophthalmology
  • AFLIBERCEPT2
    VEGF-Trap ROP
    Ophthalmology
  • ALIROCUMAB
    PCSK9 Antibody HeFH in pediatrics
    Cardiovascular & Metabolic Diseases General Medicine
  • CEMIPLIMAB5
    PD-1 Antibody First-line NSCLC chemotherapy combination, second-line cervical cancer, adjuvant CSCC
    Oncology
  • DUPILUMAB5
    IL-4R alpha subunit Antibody EoE in pediatrics; chronic obstructive pulmonary disease ("COPD"); bullous pemphigoid (Phase 2/3); chronic spontaneous urticaria ("CSU"); chronic inducible urticaria - cold; chronic rhinosinusitis without nasal polyposis; allergic fungal rhinosinusitis; chronic pruritis of unknown origin
    Immunology & Inflammation
  • FIANLIMAB
    LAG-3 Antibody First-line metastatic melanoma
    Oncology
  • GARETOSMAB
    Activin A Antibody Fibrodysplasia ossificans progressiva ("FOP")
    Rare Diseases General Medicine
  • ITEPEKIMAB5
    IL-33 Antibody COPD
    Immunology & Inflammation
  • POZELIMAB + CEMDISIRAN1
    C5 Antibody + C5 siRNA Therapeutic Myasthenia gravis cemdisiran combination, paroxysmal nocturnal hemoglobinuria ("PNH") cemdisiran combination
    Cardiovascular & Metabolic Diseases Rare Diseases Hematology
  • REGN5713-5714-5715
    Bet v 1 Multi-Antibody Therapy Birch allergy
    Immunology & Inflammation

No results found. Please adjust your filter selection and try again.

1In collaboration with Alnylam

2In collaboration with Bayer outside of the U.S.

3In collaboration with Intellia

4In collaboration with Roche outside of the U.S.

5In collaboration with Sanofi

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

Pipeline last updated:

Scientific trailblazers

Following the science leads to unexpected breakthroughs and diverse areas of study —from ophthalmology to cancer to inflammation to pain to cardiovascular disease.

Our Current Research

Explore our clinical trials

The discoveries never stop as we work to help people with serious diseases. Clinical trials allow us to carefully test and collect data about investigational products before they can be approved for use. Learn more about our clinical trials or find a relevant one near you.

Find Trials
Back
to top